がん生検市場：製品タイプ別、生検タイプ別

がん生検市場は、2025年に336億9,000万米ドルと推定され、2032年には879億9,000万米ドルに達すると予測され、2025～2032年にかけて14.7%のCAGRで成長すると予測されます。

生検とは、体内の組織片や細胞のサンプルを採取し、ラボで検査するための医療検査です。一方、がん生検では、がんの存在、原因、範囲を発見するために、罹患患者の組織または細胞を採取します。このように、世界中でがんの負担が増加しているため、がん生検またはがん生検の使用も急速なペースで増加しています。

市場力学

腫瘍性疾患の有病率の増加、高齢者の増加、リキッド生検の登場や採用の増加、遺伝子検査や遺伝性腫瘍性疾患に関する人々の意識の高まり、生検技術の継続的な開発は、世界のがん生検市場の成長を増大させると予想される主要因です。

例えば、2022年5月、早期がん発見のための高性能かつ低価格の新クラスのリキッドバイオプシー検査の開発企業であるDelfi Diagnosticsは、次世代リキッドバイオプシープラットフォームの複数の応用例を発表しました。デルフィは、肺がん検出のためのクラシファイアーの訓練と検査を行う前向き症例対照研究であるDELFI-L101の検査進行中の最新情報を発表しました。

本調査の主要特徴

• 本レポートは、世界のがん生検市場を詳細に分析し、2024年を基準年とした予測期間2025～2032年の市場規模と複合年間成長率（CAGR%）を記載しています。
• また、さまざまなセグメントにわたる潜在的な収益機会を明らかにし、この市場の魅力的な投資提案マトリクスについて解説しています。
• また、市場促進要因、抑制要因、機会、新製品の上市や承認、市場動向、地域による展望、主要企業が採用する競争戦略などに関する重要な考察も提供しています。
• 企業ハイライト、製品ポートフォリオ、主要なハイライト、業績、戦略などの以下のパラメータに基づいて、世界のがん生検市場の主要企業プロファイルを掲載しています。
• 本レポートから洞察により、マーケティング担当者や企業の経営陣は、将来の製品発売、タイプアップ、市場拡大、マーケティング戦術に関する情報に基づいた意思決定を行うことができます。
• この調査レポートは、投資家、サプライヤー、製品メーカー、流通業者、新規参入者、財務アナリストなど、この産業のさまざまな利害関係者を対象としています。
• 利害関係者は、世界のがん生検市場分析に使用される様々な戦略マトリックスを通じて、意思決定を容易にすることができます。

目次

第1章 調査の目的と前提条件

• 調査目的
• 前提条件
• 略語

第2章 市場展望

• レポートの説明
  • 市場の定義と範囲
• エグゼクティブサマリー
• 一貫型機会マップ（COM）

第3章 市場力学、規制、動向分析

• 市場力学
  • 腫瘍疾患の負担増大
  • 技術的と臨床的課題
  • 液体生検の採用増加
• 影響分析
• 規制シナリオ
• 製品の発売/承認
• PEST分析
• ポーター分析
• 合併と買収のシナリオ

第4章 がん生検市場-コロナウイルス（COVID-19）パンデミックの影響

• COVID-19疫学
• 供給側と需要側の分析
• 経済への影響

第5章 世界のがん生検市場、製品別、2020～2032年

• イントロダクション
• 機器
• キットと消耗品
• サービス

第6章 世界のがん生検市場、生検タイプ別、2020～2032年

• イントロダクション
• 組織生検
• 針生検
• 液体生検
• その他

第7章 世界のがん生検市場、用途別、2020～2032年

• イントロダクション
• 乳がん
• 大腸がん
• 子宮頸がん
• 肺がん
• 前立腺がん
• 皮膚がん
• 血液がん
• 腎臓がん
• 肝臓がん
• 膵臓がん
• 卵巣がん
• その他

第8章 世界のがん生検市場、地域別、2020～2032年

• イントロダクション
• 北米
• ラテンアメリカ
• 欧州
• アジア太平洋
• 中東

第9章 競合情勢

• QIAGEN
• Illumina, Inc.
• Angle PLC
• Myriad Genetics
• COUNSYL, Inc.
• Hologic, Inc.
• Biocept, Inc.
• Thermo Fisher Scientific, Inc.
• Danaher
• F. Hoffmann-La Roche Ltd.
• Epigenomics AG
• BD（Becton, Dickinson and Company）
• Helio Health（Laboratory for Advanced Medicine）

第10章 セクション

• 調査手法
• 出版社について

Cancer Biopsy Market is estimated to be valued at USD 33.69 Bn in 2025 and is expected to reach USD 87.99 Bn by 2032, growing at a compound annual growth rate (CAGR) of 14.7% from 2025 to 2032.

A biopsy is a medical test to remove the piece of tissue or a sample of cells from the body so that it can be tested in a laboratory. While, in cancer biopsy, a tissue or cells of the affected patient is taken to discover the presence, cause, or extent of cancer. Thus, with the rising burden of cancer across the globe, the use of cancer biopsy or cancer biopsies also increasing with a rapid pace.

Market Dynamics:

Increasing prevalence of oncology disorders, growing geriatric population, advent of liquid biopsy or increasing adoption of liquid biopsies, increasing awareness among people about genetic testing and inherited oncology diseases, and ongoing developments in biopsy techniques are major factors expected to augment the growth of the global cancer biopsy market.

For instance, in May 2022, Delfi Diagnostics, a developer of a new class of high-performance and affordable liquid biopsy tests for early cancer detection, presented multiple applications for its next-generation liquid biopsy platform. Delfi presented a trial-in-progress update on DELFI-L101, a prospective, case-control study to train and test classifiers for lung cancer detection.

Key features of the study:

• This report provides in-depth analysis of the global cancer biopsy market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period 2025-2032, considering 2024 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global cancer biopsy market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include QIAGEN, Illumina, Inc., Angle PLC, Myriad Genetics, COUNSYL, Inc., Hologic, Inc., Biocept, Inc., Thermo Fisher Scientific, Inc., Danaher, F. Hoffmann-La Roche Ltd., Epigenomics AG, BD (Becton, Dickinson and Company), and Helio Health (Laboratory for Advanced Medicine), among others.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The global cancer biopsy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global cancer biopsy market.

Detailed Segmentation:

• Global Cancer Biopsy Market , By Product:
  • Instruments
  • Kits and Consumables
  • Services
• Global Cancer Biopsy Market , By Biopsy Type:
  • Tissue Biopsy
  • Needle Biopsy
  • Fine Needle Aspiration (FNA)
  • Core Needle Biopsy (CNB)
  • Liquid Biopsy
  • Others
• Global Cancer Biopsy Market, By Application:
  • Breast Cancer
  • Colorectal Cancer
  • Cervical Cancer
  • Lung Cancer
  • Prostate Cancer
  • Skin Cancer
  • Blood Cancer
  • Kidney Cancer
  • Liver Cancer
  • Pancreatic Cancer
  • Ovarian Cancer
  • Others
• Global Cancer Biopsy Market , By Geography:
  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa
• Company Profiles:
  • QIAGEN
  • Illumina, Inc.
  • Angle PLC
  • Myriad Genetics
  • COUNSYL, Inc.
  • Hologic, Inc.
  • Biocept, Inc.
  • Thermo Fisher Scientific, Inc.
  • Danaher
  • Hoffmann-La Roche Ltd.
  • Epigenomics AG
  • BD (Becton, Dickinson and Company)
  • Helio Health (Laboratory for Advanced Medicine)

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Product
  • Market Snapshot, By Biopsy Type
  • Market Snapshot, By Application
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Rising burden of oncology disorders
  • Technical and clinical challenges
  • Increasing adoption of liquid biopsies
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Product launch/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario

4. Cancer Biopsy Market - Impact of Coronavirus (COVID-19) Pandemic

• COVID-19 Epidemiology
• Supply Side and Demand Side Analysis
• Economic Impact

5. Global Cancer Biopsy Market, By Product, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Instruments
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Kits and Consumables
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Services
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

6. Global Cancer Biopsy Market, By Biopsy Type, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Tissue Biopsy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Needle Biopsy
  • Fine Needle Aspiration (FNA)
  • Core Needle Biopsy (CNB)
• Liquid Biopsy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

7. Global Cancer Biopsy Market, By Application, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Breast Cancer
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Colorectal Cancer
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Cervical Cancer
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Lung Cancer
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Prostate Cancer
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Skin Cancer
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Blood Cancer
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Kidney Cancer
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Liver Cancer
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Pancreatic Cancer
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Ovarian Cancer
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

8. Global Cancer Biopsy Market, By Region, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Biopsy Type, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Bn)
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Biopsy Type, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Bn)
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Biopsy Type, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Bn)
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Biopsy Type, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Bn)
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Biopsy Type, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Bn)
  • Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Biopsy Type, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Bn)

9. Competitive Landscape

• QIAGEN
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Illumina, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Angle PLC
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Myriad Genetics
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• COUNSYL, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Hologic, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Biocept, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Thermo Fisher Scientific, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Danaher
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• F. Hoffmann-La Roche Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Epigenomics AG
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• BD (Becton, Dickinson and Company)
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Helio Health (Laboratory for Advanced Medicine)
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Analyst Views

10. Section

• Research Methodology
• About us